chartexchange

LifeMD: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 14, 2026 9:46 PM EST

On its third quarter of 2026 earnings call, held on Nov. 12, 2026, LifeMD (NASDAQ:LFMD) announced a strategic shift toward direct pharmacy distribution of branded glucagon-like peptide-1 (GLP-1) weight-loss medications alongside lower operating expenses. For long-term investors, the transition to direct relationships with pharmaceutical manufacturers and enterprise partnerships could reduce reliance on marketing and establish durable subscription revenue. Three key takeaways from management's comments illustrate how this business transformation is unfolding. LifeMD signed direct fulfillment arrangements with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to deliver branded obesity treatments directly to patients through its affiliated pharmacy. By handling prescribing, fulfillment, and clinical support on a single telehealth platform, the company aims to eliminate third-party friction and capture higher gross profit dollars per subscriber. Management launched a major enterprise collaboration with telecommunications provider AT&T, granting 100 million wireless and fiber customers and 110,000 employees access to complimentary memberships. This channel provides a scalable, lower-cost alternative to traditional direct-to-consumer digital marketing. Continue reading

Read original article